FibroScan by Echosens
A rapid, non-invasive, point of care liver examination.
FibroScan is a non-invasive technology that quickly provides a quantitative assessment of liver stiffness and liver fat at the point of care. As part of an overall patient assessment, FibroScan-based scores can be used to efficiently rule out the need for further assessment, like a painful liver biopsy, saving time and resources for people who do not require additional assessment for end-stage liver disease.
Different styles to support
your evolving needs
The FibroScan technology is available in different styles to support your evolving needs: FibroScan Compact, FibroScan mini. Every member of the FibroScan product family uses the same dual function technology, designed to guide the operator through the examination, to provide consistent, reliable results irrespective of system and operator.
Only FibroScan can provide dual function liver testing: Echosens patented VCTE™ and CAP™ assessments. These are simultaneously acquired during a simple, painless and time-efficient examination. Together, VCTE and CAP provide important information to assess your patients' liver health.
What is VCTE™?
FibroScan assesses liver stiffness using a patented technique called VCTE. VCTE is recognizable worldwide as the original and most extensively studied liver elastography technology for liver stiffness assessment in point of care. VCTE has been studied in over 2,000 peer-reviewed publications and is referenced across most clinical practice guidelines. In the VCTE assessment, a controlled 50Hz frequency shear wave is mechanically induced to the liver. The propagation speed of this shear wave is then measured with pulse-echo ultrasound. Scientific validation establishes that high shear wave speed correlates to high liver stiffness.
Liver stiffness assessment
- Quantification of the liver stiffness with no image provided.
- Large three cubic centimeters explored volume compensates for liver tissue heterogeneity. Exploration volume of three cubic centimeters is over 100x bigger than with needle biopsy1
- Mechanically induced 50 Hz shear wave. Shear wave speed measured with pulse echo ultrasound
- Liver stiffness calculated and expressed as a median over minimum 10 measurements
- Median measured in Kilopascals (KPa)
What is CAP™?
In addition to VCTE, FibroScan calculates the ultrasound attenuation rate within the same explored 3cm3 volume. This assessment, known as CAP, is associated with the level of fat present in the liver tissue. During the measurement, an ultrasound is generated by the FibroScan probe, the CAP measurement calculates the absorption or attenuation of this ultrasound. As fat builds up in the liver, the attenuation rate increases.
Fat approximation (CAP)
- Large three cubic centimeters explored volume
- CAP is computed from the pulse echo ultrasound signal used in VCTE
- CAP calculated and expressed as a median over minimum 10 measurements
- CAP is expressed in decibel per meter (db/m)
Different FibroScan Probes for Different Patient Types
To optimize measurement accuracy and consistency, FibroScan offers a range of probe models that match the measurement area of most patient morphology. By adjusting the measurement area relative to the distance of the liver below the surface of the skin, a consistent three cubic centimeters explored volume can be maintained.
- S+ Probe, Pediatric: Designed for pediatric patients with a thoracic perimeter less than 75cm
- M+ Probe, Medium: Designed for adults in which the distance from the skin to the liver capsule is 25mm or less.
- XL+ Probe, Extra Large: Designed for heavier weight adults in which the distance from the skin to the liver capsule is over 35mm.
Operated by an Echosens certified operator, FibroScan provides instantaneous quantitative results at the end of the examination. The treating healthcare professional will interpret these measurements based on the etiology and guidelines of their preference. With the MyFibroScan app, physicians can enter their patient’s scores, select their etiology and view a graphical representation of their patients’ scores compared to the threshold cutoff values of the selected etiology.Learn more by downloading the app
FibroScan is FDA cleared
FibroScan is the first and only point of care device specifically developed and FDA cleared as an aid to the diagnosis and monitoring of adult patients with liver disease, as part of an overall assessment of the liver. The FibroScan accuracy has been extensively studied and is the reference for many major treatment guidelines.
The intended use/indications for use for the FibroScan are as follows:
The FibroScan family of products (models:502 Touch, 530 Compact, and 430 Mini+) is intended to provide 50Hz shear wave speed measurements and estimates of tissue stiffness as well as 3.5 MHz ultrasound coefficient of attenuation (CAP: Controlled Attenuation Parameter) in internal structures of the body.
FibroScan Family of Products (Models: 502 Touch, 530 Compact, and 430 mini +) is indicated for noninvasive measurement in the liver of 50Hz shear wave speed and estimates of stiffness as well as 3.5Mhz ultrasound coefficient of attenuation (CAP: Controlled Attenuation Parameter).
The shear wave speed and stiffness, and CAP may be used as an aid to diagnosis and monitoring of adult patients with liver disease, as part of an overall assessment of the liver.
Shear wave speed and stiffness may be used as an aid to clinical management of pediatric patients with liver disease.
Additionally, FibroScan technology complies with all applicable rules governing the level of energy applied and absorbed to the human body, including mechanical indexes and heat dissipation.
FibroScan and Chronic Care Liver Disease Management
Economic Analysis Model Suggests Screening People for Fibrosis With Non-Invasive Tests Cost-effective
Echosens Cites Need for Liver Disease Monitoring for Medication Management of Psoriasis
Mederacke I, Wursthorn K, Kirschner J, Rifai K, Manns MP, Wedemeyer H, Bahr MJ. Food intake increases liver stiffness in patients with chronic or resolved hepatitis C virus infection. Liver International 2009;29:1500-1506.